XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.4
BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
segment
tranche
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Significant Accounting Policies [Line Items]        
Net income (loss) $ 141,561 $ (64,080) $ 854,029 [1],[2],[3]  
Accumulated deficit 789,199 930,760 [4]    
Stockholders' equity decrease (4,603,156) (4,265,669) [4] (4,100,931) $ (3,122,381)
Deferred tax assets 1,505,412 1,450,161 [4]    
Other assets 176,236 152,121 [4]    
Decrease in other long-term liabilities $ (100,015) (98,362) [4]    
Payment term after customer control 1 year      
Period between customer control and payment 1 year      
Advertising expenses $ 25,200 30,200 29,300  
Number of tranches in offering period | tranche 4      
Span of offering period 24 months      
Foreign currency transaction losses $ 11,400 11,700 9,900  
Number of reportable segment | segment 1      
Number of operating segments | segment 1      
ALDURAZYME net product revenues marketed by Sanofi | Minimum        
Significant Accounting Policies [Line Items]        
Payment received as percentage of net product sales 39.50%      
ALDURAZYME net product revenues marketed by Sanofi | Maximum        
Significant Accounting Policies [Line Items]        
Payment received as percentage of net product sales 50.00%      
Revision of Prior Period, Error Correction, Adjustment        
Significant Accounting Policies [Line Items]        
Net income (loss)     (5,100)  
Accumulated deficit     5,100  
Accounts payable and accrued liabilities   6,700    
Stockholders' equity decrease [5]   5,071 $ 5,071 $ 0
Deferred tax assets   1,100    
Other assets   400    
Decrease in other long-term liabilities   $ 100    
[1] Certain December 31, 2020 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.
[2] Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.
[3] December 31, 2020 Net Income has been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.
[4] Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.
[5] The years ended December 31, 2021 and 2020 have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.